Arcus Biosciences, Inc. (NASDAQ: RCUS) was founded on April 30, 2015 and is headquartered in Hayward, California, USA. It has 83 full-time employees (2/1/2018). It is a clinical-stage biopharmaceutical company focusing on using Underutilized biological opportunities to develop new cancer immunotherapies.
Arcus Biosciences, Inc. (RCUS):
Arcus Biosciences, Inc. is committed to developing new cancer immunotherapies by exploiting underutilized biological opportunities. Specifically, Arcus Biosciences targets well-characterized biological pathways with important scientific data to support their importance in regulating the immune response against cancer, and either there are no molecules in development or molecules with sub-optimal profiles. . In order to take advantage of these approaches, the company has established a powerful and efficient discovery capability to create and optimize highly differentiated small molecule immuno-oncology product candidates. Since its establishment in 2015, Arcus Biosciences has established a broad portfolio of small molecule and antibody product candidates, and the company plans to develop it as a portfolio within the product portfolio. The company has started clinical trials for its two most advanced product candidates. The two products are expected to generate data in 2018, and the first combination of clinical data is expected to be released in the first half of 2019. At the same time, Arcus Biosciences plans to advance two other product candidates into clinical trials before the end of 2018.
Members of the Arcus Biosciences, Inc. team have worked together for more than 10 years in companies such as Tularik Inc., Amgen, Inc. and Flexus Biosciences, Inc. and found innovative small molecule product candidates.
Arcus Biosciences, Inc. (RCUS) investment:
Arcus Biosciences, Inc. (NASDAQ: RCUS) landed on Nasdaq on 3/15/2018 IPO, with an issue price of US$15, 8 million shares issued, and a fund-raising of US$120 million, stock code: RCUS.